GI Deals Are Up 1100% in 2026 — Here's the Data

Eleven gastroenterology deals closed between March and September 2026 — up from exactly zero in the prior six-month window. That's a +1100% shift, and it didn't happen by accident. After years of IBD and broader GI assets being treated as niche pipeline bets behind oncology and immunology, two of the world's largest pharma companies — Roche and Eli Lilly — simultaneously moved to lock up gastroenterology licensing 2026 targets, signaling that GI has graduated from therapeutic afterthought to top-tier strategic priority.

The Data — Gastroenterology Deal Activity, Period over Period

The base-rate effect is obvious — going from zero to anything produces an eye-popping percentage. But the absolute number matters too. Eleven GI transactions in six months outpaces the annualized rate for the entire therapeutic area across most of the 2020–2025 period, when two to five deals per year was the norm. This isn't a blip. It's a regime change. You can track how this compares to other therapeutic areas on our Deal Benchmarks page.

What's Driving the Trend

1. The integrin thesis went mainstream. Roche's rapid-fire acquisitions of Morphic Therapeutic, Prometheus, and the Roivant GI asset within a two-week window in late April–May 2026 make the strategic logic unmistakable. Roche is building a next-generation IBD franchise anchored on oral integrin inhibitors — the mechanistic successor to vedolizumab (Entyvio), which generated over $8B in peak annual sales for Takeda. Morphic's oral α4β7 program was the cornerstone; Prometheus's TL1A biology and Roivant's clinical-stage assets filled adjacent positions. This wasn't portfolio diversification. It was a full-stack therapeutic area buildout executed at deal speed.

2. Lilly is playing the same game from a different angle. Eli Lilly's June 2026 deal with Hanmi Pharm (recorded twice in deal databases, reflecting overlapping announcement and execution dates) targets GI through Hanmi's peptide and bispecific platform capabilities. Lilly's GI ambitions are less public than Roche's, but the Hanmi partnership — coming from a company that has historically concentrated BD firepower on cardiometabolic and neuroscience — represents a deliberate therapeutic expansion. When the #1 and #4 pharma companies by market cap both enter a space in the same quarter, the signal is unambiguous.

3. The clinical data matured at the same time. The pipeline for GI — particularly IBD, celiac disease, and eosinophilic GI disorders — hit a clinical inflection point through 2025. Multiple Phase 2 readouts across oral integrin inhibitors, anti-TL1A antibodies, and S1P modulators generated the kind of differentiated data that triggers big-pharma BD engagement. The prior six-month drought (September 2025 to March 2026) wasn't lack of interest — it was the quiet period where pharma teams were running diligence on assets whose data packages had just matured enough to price.

Notable Deals

Roche's three-deal sprint is the defining feature of gastroenterology deal trends 2026. The Morphic acquisition (announced April 29) was followed within 48 hours by the Prometheus and Roivant transactions — a sequencing that suggests Roche had term sheets staged and executed them as a coordinated wave. This is atypical. Most pharma BD teams run one major deal at a time. Running three simultaneously in the same therapeutic area indicates board-level conviction and pre-authorized deal authority at a scale usually reserved for oncology platform plays.

The Lilly–Hanmi deal is harder to read without disclosed financial terms. Hanmi has historically structured its outbound deals as technology-access licenses with significant milestone-heavy economics. If this follows the Hanmi playbook, expect a modest upfront ($50–150M range) with substantial development and commercial milestones. The GI indication focus — rather than the cardiometabolic programs where Hanmi has more public pipeline visibility — suggests Lilly identified a specific preclinical or early clinical GI asset in Hanmi's portfolio worth securing before Roche's spending spree inflated valuations across the sector.

What This Means for BD Teams Right Now

If you're selling a GI asset, you are in the strongest negotiating position this therapeutic area has seen in a decade. Two mega-cap buyers have declared their intent publicly through deal activity. At least three to four other top-20 pharma companies (AbbVie, Pfizer, J&J, AstraZeneca) have significant GI commercial infrastructure and will be forced to respond competitively. The window for premium-priced gastroenterology licensing 2026 deals is open — but it has a shelf life. Once Roche's integrin portfolio enters Phase 3 and the competitive map crystallizes, the urgency to acquire diminishes.

If you're buying, move now and structure aggressively. The deals that haven't happened yet — the mid-tier GI biotechs with Phase 1/2 oral assets in IBD, celiac, or eosinophilic esophagitis — are watching these headlines and recalibrating their expectations upward. Every week of delay is a valuation headwind. The smart move is to lock in option-based deal structures: co-development agreements, opt-in rights at Phase 2 data, or structured acquisitions with CVRs tied to clinical milestones. Pure upfront-heavy licensing is becoming expensive in this environment. Use Solidus to model how current deal structures compare to historical GI benchmarks.

Deal structure trends to watch: Expect more M&A relative to licensing in GI through the back half of 2026. When a buyer like Roche executes three acquisitions in two weeks, it signals that the premium for full ownership — versus optionality via licensing — has become justifiable. Biotech boards holding differentiated GI assets should be running dual-track processes (IPO + M&A) to maximize leverage. BD teams at pharma should be prepared to compete against acquisition offers, not just other license term sheets.

Benchmark your deal against current market rates using the Ambrosia calculator. With gastroenterology deal activity up 1100% and two mega-pharma buyers actively competing, understanding where your terms sit relative to the market is no longer optional — it's the difference between capturing the cycle and getting left behind.